ADHD Trial, Recruiting NCT06858527 Sponsor: Assistance Publique - Hôpitaux de Paris Condition: ADHD
Back to Adhd

ADHD Trial, Recruiting

NCT06858527
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 or older
  • People who have been diagnosed with at least one moderate to severe substance use disorder (not including tobacco) according to standard diagnostic criteria (DSM-5)
  • People who are currently receiving treatment for a substance use disorder from a doctor or psychologist
  • People who have been diagnosed with ADHD (Attention Deficit Hyperactivity Disorder) using a specific diagnostic tool called the DIVA 2.0 or DIVA-5
  • People who have health insurance coverage
  • People who can understand and communicate in French
  • People who have signed a consent form agreeing to participate

Who may not be able to join:

  • People under the age of 18
  • People who are pregnant or breastfeeding
  • People who have not signed the consent form
  • People who have significant difficulty understanding or communicating in French
  • People with severe cognitive impairment (serious difficulties with thinking, memory, or understanding)
  • People with a serious medical condition that would make participation in assessments or group sessions impossible or unsafe
  • People whose substance use disorder is being managed in a controlled or protected environment (such as a residential facility), currently or within the last 15 days, or expected to be during the study
  • People whose only substance use disorder involves tobacco
  • People who are under legal guardianship
  • People who are currently detained or under a court-ordered supervision arrangement
  • People who are already participating in another group-based psychological therapy during the period when this trial's group sessions are running

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Norman Therribout, PhD, Paris-Nanterre University, UR-4430 CLIPSYD ; Paris-Cité University, UMR-S-1144 INSERM; Fernand-Widal Hospital AP-HP

Phone: +33140054464

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 April 2025
Est. completion
1 July 2029

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Emotion dysregulation

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov